Oncimmune

Immunodiagnostics company developing biomarker platforms for cancer and immune diseases

placeCambridge, Massachusetts, United States calendar_todayFounded 2006 groups62 employees language oncimmune.com

Registered entities

Innovation

18 patent families (11 granted) — focus: Physics & computing, Chemistry & metallurgy, Emerging technologies; filing pace slowing. Cited 3,045 times.

YearFilings
20126
20137
20147
20156
20166
20177
20185
20192
20202
20212
20224
20231

Social engagement

Social engagement: 5.7K social following, 4 posts in the last 12 months — around the industry typical range.

Investor mix

11 investors on record.

Investor typeCountShare
Venture capital436%
Private equity218%
Bank & private debt218%
Other / undisclosed327%

Recent activity

4 Mar 2026
Event
Alden Scientific CEO Jamie Heywood at The National Academies of Sciences, Engineering, and Medicine
17 Feb 2026
Event
BIOEuropeSpring
Coming soon